<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="370">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156333</url>
  </required_header>
  <id_info>
    <org_study_id>AOU 0025949/19</org_study_id>
    <nct_id>NCT05156333</nct_id>
  </id_info>
  <brief_title>Probiotics and GBS Colonization in Pregnancy</brief_title>
  <official_title>Probiotics in Pregnancy and Rectovaginal Group B Streptococcus (GBS) Colonization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daniela Menichini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Longo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Modena and Reggio Emilia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric, randomized, placebo-controlled, double-blind, parallel group study aimed at&#xD;
      evaluating the feasibility and effect of the use of probiotic starting from the 30th week, on&#xD;
      vaginal / rectal colonization of GBS in women at low obstetric risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, randomized, placebo-controlled, double-blind, parallel group study aimed at&#xD;
      evaluating the feasibility and effect of the use of probiotic starting from the 30th week, on&#xD;
      vaginal / rectal colonization of GBS in women at low obstetric risk.&#xD;
&#xD;
      The study includes low obstetric risk pregnant women within the 33rd week of gestation, with&#xD;
      vaginal delivery expected. It excludes women who during pregnancy had a positive urine&#xD;
      culture for GBS, women with a previous newborn suffering from early sepsis, use of&#xD;
      antibiotics in the month prior to enrollment, women unable to understand the study and sign&#xD;
      informed consent.&#xD;
&#xD;
      Intervention Daily oral administration of two capsules of the Giellepi Spa class IIa medical&#xD;
      device &quot;Respecta&quot; or placebo, to be taken with a glass of water preferably between meals,&#xD;
      starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab&#xD;
      screening performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group study aimed at underestimating the feasibility and effect of the use of probiotic starting from week 30 on vaginal / rectal colonization of GBS in women at low obstetric risk.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The randomization (1: 1) will take place in each center, using the same allocation sequence, in blocks of 4, with the indication of the treatment code inserted in a white, closed envelope. The code will correspond to the number written on the packages to be administered and the list of codes containing the definition of the treatments, will be kept in a sealed envelope, by a collaborator of the PI (Head Nurse), and opened upon completion of the study or at the time of need, in case maternal-fetal or neonatal serious adverse event.&#xD;
No member of the research team knows which treatment the patients receive because both the active and the placebo are packaged identically and are contained in identical white boxes. Only the randomization numbers distinguish them.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>GBS Rectovaginal colonization</measure>
    <time_frame>at 35-37 weeks</time_frame>
    <description>Rate of colonized GBS pregnant (carriers) at the time of antepartum screening (35-37 ^ week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intrapartum antibiotics profilaxisi</measure>
    <time_frame>during labor</time_frame>
    <description>Rata of women requiring antibiotic profilaxis intrapartum</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PROM</measure>
    <time_frame>pre-labor</time_frame>
    <description>Prelabor rupture of membranes evaluated according to clinical signs or fibronectin test</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathologic APGAR score</measure>
    <time_frame>at delivery</time_frame>
    <description>The Apgar score is a measure of a baby's condition after birth. It guides midwives, doctors and nurses as to whether a baby needs immediate treatment or monitoring. It is used to check a newborn baby born at 1 minute and 5 minutes after their birth. It is named after Dr Virginia Apgar who developed the score.&#xD;
The Apgar score goes from 0 to 10 and it is classified as pathologic when is &lt;/= 7</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for neonatal antibiotics</measure>
    <time_frame>within the first 48 hours after birth</time_frame>
    <description>Rate of neonates requiring antibiotics within the first 48h of life</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal sepsis</measure>
    <time_frame>within the first week after birth</time_frame>
    <description>Rate of neonates developing a sepsis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>GBS Rectovaginal Colonization</condition>
  <condition>Neonatal Sepsis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral administration of 1 capusle of placebo, composed of: hydroxypropylmethylcellulose; Anti-caking agent: Magnesium salts of fatty acids, Dioxide of silicon; Dye: E171.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily oral administration of 1 capsule of mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Respecta</intervention_name>
    <description>Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).&#xD;
Daily oral administration of two capsules of the Giellepi Spa class IIa medical device &quot;Respecta&quot; or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Probiotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  low obstetric risk pregnant women by the 33rd week of gestation,&#xD;
&#xD;
          -  vaginal delivery expected.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  positive urine culture for GBS,&#xD;
&#xD;
          -  previous newborn suffering from early sepsis,&#xD;
&#xD;
          -  use of antibiotics in the month prior to enrollment,&#xD;
&#xD;
          -  women unable to understand the study and sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniela ì R Menichini, PhD</last_name>
    <phone>3406357360</phone>
    <email>daniela.menichini91@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio Facchinetti, MD</last_name>
    <phone>0594223553</phone>
    <email>fabio.facchinetti@unimore.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale dei Bambini &quot;Vittore Buzzi&quot;</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20154</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Mastrolia, MD</last_name>
      <email>mastroliasa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Irene Cetin, MD</last_name>
      <email>irene.cetin@unimi.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Santagni, MD</last_name>
      <email>susanna.santagni@ausl.re.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Facchinetti, MD</last_name>
      <phone>+39 0594225334</phone>
      <email>fabio.facchinetti@unimore.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Modena and Reggio Emilia</investigator_affiliation>
    <investigator_full_name>Prof. Fabio Facchinetti</investigator_full_name>
    <investigator_title>Director of the Obstetrics and Gynecolocy department</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>GBS colonization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

